TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sino Biopharmaceutical ( (HK:1177) ) has shared an announcement.
Sino Biopharmaceutical Limited has announced the approval of its Rotigotine Patch by the National Medical Products Administration of China for the treatment of early idiopathic Parkinson’s disease. This approval signifies a major advancement in their transdermal patch offerings, expected to enhance patient compliance and symptom control, while solidifying the company’s position as a leader in neurological disorder treatments.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company involved in the pharmaceutical industry, focusing on the development and marketing of transdermal patch treatments for neurological disorders. Their primary products include treatments for diseases such as Parkinson’s and Alzheimer’s, leveraging a proprietary solvent-based transdermal patch platform.
Average Trading Volume: 103,324,666
Technical Sentiment Signal: Buy
Current Market Cap: HK$123.8B
Learn more about 1177 stock on TipRanks’ Stock Analysis page.